查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1439638

下一代定序 (NGS) - 全球市场考量、竞争格局、市场预测 (2030)

Next Generation Sequencing - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: 按订单生产 | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

2023年全球下一代定序（NGS）市场规模将达到92.8亿美元，到2030年将达到263亿美元，2024-2030年预测期内复合年增长率为18.96%，预计将持续增长。 对次世代定序 (NGS) 的需求增加主要是由于传染病病例的增加（例如 COVID-19 的突发爆发）以及全球癌症负担的增加。 此外，NGS技术在临床诊断和科学研究中的应用日益增多，NGS技术所展现出的高效週转结果、高速和准确等优势预计将在未来几年推动全球下一代定序（NGS）市场。

次世代定序 (NGS) 市场动态

由于全球 COVID-19 病例的快速增加，下一代定序 (NGS) 市场目前正在快速成长。 这是因为新冠病毒自爆发以来已经发生了进化，PCR检测只能确定病毒的存在。 同时，NGS 技术用于确定和监测 COVID-19 病毒的新病毒株。

根据世界卫生组织 (WHO) 的数据，截至 2022 年 12 月 22 日，全球已报告约 275,233,892 例 COVID-19 确诊病例。

此外，全球癌症患者负担的增加预计也将为次世代定序（NGS）市场做出贡献。 这是由于基于 NGS 技术的平台在癌症生物标记检测中的重要性日益增加。 根据 GLOBOCAN 目录 2020 年公布的数据，同年全球共发现约 19,292,789 例新癌症病例。

此外，用于检测传染病和遗传性疾病等各种疾病的基于NGS技术的产品的批准预计将在预测期内为下一代定序（NGS）市场做出贡献。 例如，2020年9月8日，美国FDA宣布推出一款伴随药物，用于识别RET融合基因阳性的转移性非小细胞肺癌（NSCLC）患者，这些患者是GAVRETO（TM）（pralsetinib）的候选者，这是一种标靶治疗药物我们已批准 Thermo Fisher Scientific 开发的 Oncomine Dx Target 测试作为诊断试剂 (CDx)。 GAVRETO(TM) 是第一个基于下一代定序 (NGS) 的 CDx 标靶生物标记物，与 FDA 批准的三种非小细胞肺癌治疗相关。

然而，NGS 技术中的引线长度短、设备和服务成本高等某些因素可能会阻碍次世代定序 (NGS) 市场的成长。

前所未有的 COVID-19 大流行对次世代定序 (NGS) 市场产生了正面影响。 NGS 技术是一种经济高效的用于诊断 COVID-19 的分子测试，因为它使用单步 RNA 提取，并且与黄金标准 RT-qPCR 相比具有较高的可扩展性和准确性。 此外，针对 SARS-CoV-2 的次世代定序 (NGS) 测试的紧急使用授权 (EUA) 的增加也导致了大流行危机期间的市场成长。 例如，2020 年 6 月 10 日，Illumina, Inc. 获得了 Illumina COVID-19 -19Seq(TM) 测试的紧急使用授权 (EUA)。 此外，采用下一代定序（NGS）技术作为临床诊断测试以及各实验室爆发的COVID-19大流行等也增强了大流行期间的市场。 例如，2020 年 8 月，Helix 实验室宣布，开发的基于扩增子的下一代定序仪用于定性检测疑似 COVID-19 患者上呼吸道标本中的 SARS-CoV-2 衍生核酸。获得 FDA 批准COVID- 19 NGS 测试。

本报告提供了全球下一代定序 (NGS) 市场的研究和分析，包括市场规模和预测、驱动因素和挑战以及公司和产品概况。

目录

第1章次世代定序 (NGS) 市场报告简介

第 2 章次世代定序 (NGS) 市场执行摘要

  • 调查范围
  • 市场概览
  • 竞争评估
  • 财务基准

第3章监理与专利分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第4章次世代定序（NGS）市场主要因素分析

  • 次世代定序 (NGS) 市场驱动因素
    • 世界各地的癌症负担日益增加
    • 全球新冠肺炎 (COVID-19) 等传染病的发生率不断上升
    • 快速核准下一代定序 (NGS) 产品
    • 次世代定序 (NGS) 产品生产的技术进步
  • 次世代定序 (NGS) 市场的限制与挑战
    • 与次世代定序 (NGS) 仪器和服务相关的高成本
    • 大多数基于 NGS 的平台上的读长较短
  • 次世代定序 (NGS) 市场机遇
    • 低收入和中等收入国家拥有下一代定序 (NGS) 市场的重大机会
    • 全球和区域製造商的策略业务活动为下一代定序 (NGS) 市场创造了机会

第 5 章次世代定序 (NGS) 的波特五力分析

第6章 COVID-19 对次世代定序 (NGS) 市场的影响分析

第7章次世代定序（NGS）市场布局

  • 依产品类型
    • 设备
    • 试剂/消耗品
    • 服务
  • 依定序类型
    • 全基因组定序
    • 全外显子定序
    • RNA定序
    • 标靶定序
    • 从头定序
    • 其他
  • 依用途
    • 诊断
    • 药物发现
    • 农业/动物研究
  • 按最终用户
    • 製药和生技公司
    • 医院/诊所
    • 学术/研究机构
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他领域

第 8 章次世代定序 (NGS)：全球公司占有率分析 - 3 至 5 家主要公司

第 9 章次世代定序 (NGS) 公司与产品简介

  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies, Inc.
  • Illumina Inc
  • Bio-Rad Laboratories, Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • PerkinElmer Inc.
  • MedGenome
  • BGI
  • Pacific Biosciences
  • GENEWIZ
  • Oxford Nanopore Technologies plc.
  • Psomagen, Inc.
  • 10x Genomics
  • Takara Bio Inc.
  • Zymo Research Corporation.
  • NuGEN Technologies, Inc. (Tecan Trading AG)
  • Vela Diagnostics
  • CD Genomics.
  • HTG Molecular Diagnostics, Inc.

第10章KOL观看次数

第 11 章专案方法

第 12 章关于 DelveInsight

第 13 章免责声明与联络我们

Product Code: DIMDCL0475

Next-Generation Sequencing Market By Product Type (Instruments, Reagents & Consumables And Services), By Sequencing Type (Whole-Genome Sequencing, Whole-Exome Sequencing, Rna Sequencing, Targeted Sequencing, De-Novo Sequencing, Others), By Application (Diagnostic, Drug Discovery, Agriculture & Animal Research, Others), By End-User (Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Academic & Research Institute), by geography, is expected to grow at a significant CAGR forecast till 2030 owing to the rising application of next-generation sequencing (NGS) technology in clinical diagnosis and advancement in NGS platforms

The global Next-Generation Sequencing market was valued at USD 9.28 billion in 2023, growing at a CAGR of 18.96% during the forecast period from 2024 to 2030, to reach USD 26.30 billion by 2030. The increase in demand for Next-Generation Sequencing is primarily attributed to the rising cases of infectious diseases such as the sudden outbreak of COVID-19 and the escalating burden of cancer, worldwide. Moreover, the rising application of NGS technology in clinical diagnosis and scientific research, and advantages such as efficient turnaround results, high speed, and accuracy exhibited by the NGS technology, among others are some of the factors that would contribute to the global Next-Generation Sequencing market growth in the forthcoming years.

Next-Generation Sequencing Market Dynamics:

The market for Next-Generation Sequencing is gaining pace at present due to the surge in COVID-19 infected people across the globe. This is because the Covid virus has evolved from the time of its outbreak and PCR testing only determines the presence of the virus. Whereas, NGS technology is used in determining the novel strains of the COVID-19 virus as well as its surveillance.

According to the World Health Organization (WHO), 22 December 2022 data, approximately 275,233,892 confirmed cases of COVID-19 were reported across the globe.

In addition, the increasing burden of cancer cases worldwide is also anticipated to contribute to the Next-Generation Sequencing market. This is because of the rising significance of NGS technology-based platforms for the detection of cancer biomarkers. According to the data published by the GLOBOCAN directory in the year 2020, approximately 19,292,789 new cases of cancer were detected, globally in the same year.

Furthermore, NGS technology-based product approvals for the detection of various disorders such as infectious diseases, genetic disorders, among others are expected to contribute to the market for Nex Generation Sequencing during the forecasted period. For instance, on September 08, 2020, the US FDA granted pre-market approval to the Oncomine Dx Target test, developed by Thermo Fisher Scientific, as a companion diagnostic (CDx) to identify RET fusion-positive, metastatic non-small cell lung cancer (NSCLC) patients who are candidates for GAVRETO(TM) (pralsetinib), a targeted therapy developed by Blueprint Medicines. It is the first targeted next-generation sequencing (NGS)-based CDx for biomarkers associated with three FDA-approved NSCLC therapies.

However, certain factors such as short read lengths in NGS technology and the high cost of the instruments & services are likely to impede the Next-Generation Sequencing market growth.

The unprecedented COVID-19 pandemic has had a positive effect on the Next-Generation Sequencing market. This is because NGS technology is a cost-effective molecular test for the diagnosis of COVID19, which uses a single-step RNA extraction and presents high scalability and accuracy when compared to the gold-standard RT-qPCR. Furthermore, the rise in emergency use authorizations (EUAs) for Next-Generation Sequencing tests for SARS-CoV-2 has also led to market growth during the pandemic crisis. For instance, on June 10, 2020, Illumina, Inc. received an Emergency Use Authorization (EUA) for the Illumina COVIDSeq(TM) Test, a high-throughput, next-generation sequencing-based, in vitro diagnostic (IVD) workflow enabling the detection of SARS-CoV-2 by the US FDA. In addition, the inclusion of Next-generation sequencing (NGS) technology as a clinical diagnostic test, particularly with the COVID-19 pandemic by various laboratories has also bolstered the market during the pandemic. For instance, in August 2020, Helix Laboratory obtained the FDA approval for its COVID-19 NGS test, an amplicon-based next-generation sequencing (NGS) test developed for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens for COVID-19 suspected individuals.

Next-Generation Sequencing Market Segment Analysis:

Next-Generation Sequencing Market By Product Type (Instruments, Reagents & Consumables And Services), By Sequencing Type (Whole Genome Sequencing, Whole Exome Sequencing, RNA Sequencing, Targeted Sequencing, De-Novo Sequencing, Others), By Application (Diagnostic, Drug Discovery, Agriculture & Animal Research, Others), By End-User (Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Academic & Research Institute), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the Next-Generation Sequencing sequencing type segment, the whole genome sequencing (WGS) type is anticipated to hold a significant market share during the forecasted period. This is because whole-genome sequencing provides the most comprehensive data related to any organism in a short duration of time. Moreover, WGS is extensively used to develop precision medicines and personalized treatment.

For instance, on December 03, 2020, Weill Cornell Medicine, New York-Presbyterian Hospital, and Illumina, Inc. entered into a collaboration to sequence the complete human genomes of thousands of consenting patients seeking to advance the scope of precision medicine.

In addition, shifting the focus of market players towards the development of NGS-based whole genome sequencing panels for the detection of causative agents of various infections such as COVID-19 would also contribute to the segmental growth of the Next-generation Sequencing market in the upcoming years. For instance, in March 2020, the Paragon Genomics team quickly developed and launched an amplicon-based NGS panel: CleanPlex® SARS-CoV-2 Panel for sequencing the whole genome of SARS-CoV-2 (the virus responsible for COVID-19) on both Illumina and MGI Tech Sequencing platforms. The panels are designed to obtain complete viral genomes even from samples with very low SARS-CoV-2 viral content.

Thus, the aforementioned factors are projected to propel the market for next-generation based whole genome sequencing type during the forecasted period.

North America is expected to dominate the overall Next-Generation Sequencing Market:

Among all the regions, North America is expected to occupy a major share in the overall Next-Generation Sequencing market during the forecasted period. This domination is owing to the rising cases of infectious disease in the region. Furthermore, the spike in the new cancer cases, the presence of key market players and leading national clinical laboratories, and favorable reimbursement policies for the NGS technology, among others are expected to fuel the overall Next-Generation Sequencing market in the region.

For instance, on January 27, 2020, the Centers for Medicare & Medicaid Services (CMS), announced to cover FDA approved or cleared laboratory diagnostic tests using Next Generation Sequencing (NGS) for patients with germline (inherited) ovarian or breast cancer.

Moreover, a rise in research and development activities to develop advanced NGS-based instruments would contribute to the regional market. For instance, in the year 2020, DNA Script and its Molecular Encoding Consortium partners were awarded a USD 23 million multi-phase contract from the Intelligence Advanced Research Projects Activity's (IARPA) Molecular Information Storage (MIST) program. The consortium will explore the possibility of integrating a novel enzymatic DNA synthesis technology and next-generation sequencing into a single instrument throughout the program.

In addition, the rise in cancer cases in the country would also lead to an increased demand for NGS sequencing technology to provide a molecular rationale for appropriate targeted therapy. For instance, according to the data published by the GLOBOCAN directory in the year 2020, approximately, 2,281,658 new cases of cancer were reported in the US in the same year.

Additionally, strategic business activities in the region to use NGS technology to enhance the diagnostic capabilities will also contribute to the NGS market in the country during the forthcoming years. For instance, on August 12, 2020, GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc., an OPKO Health company agreed with Pediatrix Medical Group to offer state-of-the-art, next-generation genomic sequencing to contribute to the clinical diagnosis in neonatal intensive care units ("NICUs") staffed by Pediatrix's affiliated neonatologists.

Hence, all the above-mentioned factors are projected to fuel the Next-Generation Sequencing market in the country.

Further, the Asia Pacific region has the future potential for the Next-Generation Sequencing market. This is predominantly due to the burgeoning cases of various infectious diseases, and the growing cancer burden in the region. Moreover, the presence of regional companies focused on developing and manufacturing advanced NGS-based systems would propel the market during the forecasted period. For instance, in 2019, Longas Technologies Pty Ltd launched Morphoseq(TM), a disruptive technology designed to improve the performance of industry-standard NGS platforms by increasing effective read lengths, with benefits in accuracy and cost-efficiency. Also, the presence of several NGS service providers in the region would contribute to the market. For instance, MedGenome offers Next Generation Sequencing services to more than 8000 clinicians with over 1600 hospitals across South Asia and India.

Moreover, rising cases of Covid-19 in the region will escalate the demand for Next-Generation Sequencing. For instance, about 34,765,976 confirmed COVID-19 cases, and 7,495 new cases were reported in India till December 23, 2022, as per the WHO report. Also, improving healthcare infrastructure, and government initiatives in raising awareness regarding molecular diagnosis will contribute to the Next-Generation Sequencing market growth in these regions.

Next-Generation Sequencing Market Key Players:

Some of the key market players operating in the Next-Generation Sequencing market include Agilent Technologies, Inc., Illumina Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, QIAGEN, Thermo Fisher Scientific, PerkinElmer Inc., MedGenome, BGI, Pacific Biosciences, GENEWIZ, Oxford Nanopore Technologies plc., Psomagen, Inc., 10x Genomics, Takara Bio Inc., Zymo Research Corporation., NuGEN Technologies, Inc. (Tecan Trading AG), Vela Diagnostics, CD Genomics., HTG Molecular Diagnostics, Inc., and others.

Recent Developmental Activities in the Next-Generation Sequencing Market:

In December 2022, Roche launched the AVENIO Edge System to simplify and automate next-generation sequencing sample preparation, reduce human error and advance precision medicine.

In May 2022, Illumina, Inc. and Next-Generation Genomics Co., Ltd. launched VeriSeq(TM) NIPT Solution v2 in Thailand, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT).

In February 2022, INOVIO and QIAGEN expanded collaboration to develop next-generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia.

Key Takeaways from the Next-Generation Sequencing Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Next-Generation Sequencing market.

Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years

Key companies dominating the Global Next-Generation Sequencing Market.

Various opportunities available for the other competitor in the Next-Generation Sequencing Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Next-Generation Sequencing market growth in the coming future?

Target Audience who can be benefited from the Next-Generation Sequencing Market Report Study

Next-Generation Sequencing providers

Research organizations and consulting companies

Next-Generation Sequencing-related organization, association, forum, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders in Next-Generation Sequencing

Various End-users who want to know more about the Next-Generation Sequencing Market and the latest technological developments in the Next-Generation Sequencing market.

Frequently Asked Questions for the Next-Generation Sequencing Market:

1. What is Next-Generation Sequencing?

Next-Generation Sequencing is a massively parallel technology for determining the RNA or DNA sequence to provide information regarding genetic variation associated with diseases or other biological phenomena. The technology offers scalability, high throughput, and speed thereby allowing labs to perform a wide variety of applications.

2. What is the market for Global Next-Generation Sequencing?

The global Next-Generation Sequencing market was valued at USD 9.28 billion in 2023, growing at a CAGR of 18.96% during the forecast period from 2024 to 2030, to reach USD 26.30 billion by 2030.

3. What are the drivers for the Global Next-Generation Sequencing?

The major factors driving the demand for Next-Generation Sequencing are the rising cases of infectious diseases such as the COVID-19 pandemic, and others. In addition, technological advancement, increasing incidence of cancer across the globe, and rapid product approvals in the Next-Generation Sequencing product arena are expected to augment the global Next-Generation Sequencing market.

4. What are the key players operating in Global Next-Generation Sequencing?

Some of the key market players operating in the Next-Generation Sequencing market include Agilent Technologies, Inc., Illumina Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, QIAGEN, Thermo Fisher Scientific, PerkinElmer Inc., MedGenome, BGI, Pacific Biosciences, GENEWIZ, Oxford Nanopore Technologies plc., Psomagen, Inc., 10x Genomics, Takara Bio Inc., Zymo Research Corporation., NuGEN Technologies, Inc. (Tecan Trading AG), Vela Diagnostics, CD Genomics., HTG Molecular Diagnostics, Inc., and others.

5. Which region has the highest share in the Next-Generation Sequencing market?

Among all the regions, North America is expected to occupy a major share in the overall Next-Generation Sequencing market during the forecasted period, 2024-2030. This domination is owing to the rising cases of infectious disease in the region. Furthermore, the spike in the new cancer cases, the presence of key market players and leading national clinical laboratories, and favorable reimbursement policies for the NGS technology, among others are expected to fuel the overall Next-Generation Sequencing market in the region.

Table of Contents

1.Next-Generation Sequencing Market Report Introduction

2.Next-Generation Sequencing Market Executive summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment
  • 2.4 Financial Benchmarking

3. Regulatory and Patent Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. Next-Generation Sequencing Market Key factors analysis

  • 4.1 Next-Generation Sequencing Market Drivers
    • 4.1.1 The rising burden of cancer worldwide
    • 4.1.2 Growing incidence of infectious diseases such as COVID-19 across the globe
    • 4.1.3 Rapid approval of Next-Generation Sequencing products
    • 4.1.4 Technological advancement in the manufacturing of Next-Generation Sequencing products
  • 4.2 Next-Generation Sequencing Market Restraints and Challenges
    • 4.2.1 High cost associated with Next-Generation Sequencing instruments and services
    • 4.2.2 Short Read Lengths in most of the NGS based platform
  • 4.3 Next-Generation Sequencing Market Opportunities
    • 4.3.1 Low and middle-income nations have tremendous opportunities for the Next-Generation Sequencing market
    • 4.3.2 Strategic business activities by the global as well as regional manufacturers will provide opportunities in the Next-Generation Sequencing market

5. Next-Generation Sequencing Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Next-Generation Sequencing Market

7. Next-Generation Sequencing Market layout

  • 7.1 By Product Type
    • 7.1.1 Instruments
    • 7.1.2 Reagents & Consumables
    • 7.1.3 Services
  • 7.2 By Sequencing Type
    • 7.2.1 Whole Genome Sequencing
    • 7.2.2 Whole Exome Sequencing
    • 7.2.3 RNA Sequencing
    • 7.2.4 Targeted Sequencing
    • 7.2.5 De-Novo Sequencing
    • 7.2.6 Others
  • 7.3 By Application
    • 7.3.1 Diagnostic
    • 7.3.2 Drug Discovery
    • 7.3.3 Agriculture & Animal Research
    • 7.3.4 Others
  • 7.4 By End-user
    • 7.4.1 Pharmaceutical & Biotechnology Companies
    • 7.4.2 Hospitals & Clinics
    • 7.4.3 Academic & Research Institute
  • 7.5 By Geography
    • 7.5.1 North America
      • 7.5.1.1 North America Next-Generation Sequencing Market, by Product Type
      • 7.5.1.2 North America Next-Generation Sequencing Market, by Sequencing Type
      • 7.5.1.3 North America Next-Generation Sequencing Market, by Application
      • 7.5.1.4 North America Next-Generation Sequencing Market, by End User
      • 7.5.1.5 North America Next-Generation Sequencing Market, by Country
      • 7.5.1.5.1 United States
      • 7.5.1.5.2 Canada
      • 7.5.1.5.3 Mexico
    • 7.5.2 Europe
      • 7.5.2.1 Europe Next-Generation Sequencing Market, by Product Type
      • 7.5.2.2 Europe Next-Generation Sequencing Market, by Sequencing Type
      • 7.5.2.3 Europe Next-Generation Sequencing Market, by Application
      • 7.5.2.4 Europe Next-Generation Sequencing Market, by End User
      • 7.5.2.5 Europe Next-Generation Sequencing Market, by Country
      • 7.5.2.5.1 France
      • 7.5.2.5.2 Germany
      • 7.5.2.5.3 United Kingdom
      • 7.5.2.5.4 Italy
      • 7.5.2.5.5 Spain
      • 7.5.2.5.6 Russia
      • 7.5.2.5.7 Rest of Europe
    • 7.5.3 Asia-Pacific
      • 7.5.3.1 Asia-Pacific Next-Generation Sequencing Market, by Product Type
      • 7.5.3.2 Asia-Pacific Next-Generation Sequencing Market, by Sequencing Type
      • 7.5.3.3 Asia-Pacific Next-Generation Sequencing Market, by Application
      • 7.5.3.4 Asia-Pacific Next-Generation Sequencing Market, by End User
      • 7.5.3.5 Asia-Pacific Next-Generation Sequencing Market, by Country
      • 7.5.3.5.1 China
      • 7.5.3.5.2 Japan
      • 7.5.3.5.3 India
      • 7.5.3.5.4 Australia
      • 7.5.3.5.5 South Korea
      • 7.5.3.5.6 Rest of Asia Pacific
    • 7.5.4 Rest of the World (RoW)
      • 7.5.4.1 RoW Next-Generation Sequencing Market, by Product Type
      • 7.5.4.2 RoW Next-Generation Sequencing Market, by Sequencing Type
      • 7.5.4.3 RoW Next-Generation Sequencing Market, by Application
      • 7.5.4.4 RoW Next-Generation Sequencing Market, by End User
      • 7.5.4.5 RoW Next-Generation Sequencing Market, by Region
      • 7.5.4.5.1 Middle East
      • 7.5.4.5.2 Africa
      • 7.5.4.5.3 South America

8. Next-Generation Sequencing Global Company Share Analysis - Key 3-5 Companies

9. Next-Generation Sequencing Company and Product Profiles

  • 9.1 F. Hoffmann-La Roche Ltd
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4 Product Listing
    • 9.1.5. Entropy
  • 9.2 Agilent Technologies, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4 Product Listing
    • 9.2.5. Entropy
  • 9.3 Illumina Inc
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4 Product Listing
    • 9.3.5. Entropy
  • 9.4 Bio-Rad Laboratories, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4 Product Listing
    • 9.4.5. Entropy
  • 9.5 QIAGEN
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4 Product Listing
    • 9.5.5. Entropy
  • 9.6 Thermo Fisher Scientific Inc.
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4 Product Listing
    • 9.6.5. Entropy
  • 9.7 PerkinElmer Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4 Product Listing
    • 9.7.5. Entropy
  • 9.8 MedGenome
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4 Product Listing
    • 9.8.5. Entropy
  • 9.9 BGI
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4 Product Listing
    • 9.9.5. Entropy
  • 9.10 Pacific Biosciences
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4 Product Listing
    • 9.10.5. Entropy
  • 9.11 GENEWIZ
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4 Product Listing
    • 9.11.5. Entropy
  • 9.12 Oxford Nanopore Technologies plc.
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4 Product Listing
    • 9.12.5. Entropy
  • 9.13 Psomagen, Inc.
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4 Product Listing
    • 9.13.5. Entropy
  • 9.14 10x Genomics
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4 Product Listing
    • 9.14.5. Entropy
  • 9.15 Takara Bio Inc.
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4 Product Listing
    • 9.15.5. Entropy
  • 9.16 Zymo Research Corporation.
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4 Product Listing
    • 9.16.5. Entropy
  • 9.17 NuGEN Technologies, Inc. (Tecan Trading AG)
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4 Product Listing
    • 9.17.5. Entropy
  • 9.18 Vela Diagnostics
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4 Product Listing
    • 9.18.5. Entropy
  • 9.19 CD Genomics.
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4 Product Listing
    • 9.19.5. Entropy
  • 9.20 HTG Molecular Diagnostics, Inc.
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4 Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us

List of Tables

  • Table 1 Competitive Analysis
  • Table 2 COVID-19 Impact Analysis on Next-Generation Sequencing Market
  • Table 3 Next-Generation Sequencing Market Analysis in Global (2021-2030)
  • Table 4 Next-Generation Sequencing Market Analysis in Global by Product Type (2021-2030)
  • Table 5 Next-Generation Sequencing Market Analysis in Global by Sequencing Type (2021-2030)
  • Table 6 Next-Generation Sequencing Market Analysis in Global by Application (2021-2030)
  • Table 7 Next-Generation Sequencing Market Analysis in Global by End User (2021-2030)
  • Table 8 Next-Generation Sequencing Market Analysis in Global by Geography (2021-2030)
  • Table 9 Next-Generation Sequencing Market Analysis in North America (2021-2030)
  • Table 10 Next-Generation Sequencing Market Analysis in North America by Product Type (2021-2030)
  • Table 11 Next-Generation Sequencing Market Analysis in North America by Sequencing Type (2021-2030)
  • Table 12 Next-Generation Sequencing Market Analysis in North America by Application (2021-2030)
  • Table 13 Next-Generation Sequencing Market Analysis in North America by End User (2021-2030)
  • Table 14 Next-Generation Sequencing Market Analysis in North America by Country (2021-2030)
  • Table 15 Next-Generation Sequencing Market Analysis in the US (2021-2030)
  • Table 16 Next-Generation Sequencing Market Analysis in Canada (2021-2030)
  • Table 17 Next-Generation Sequencing Market Analysis in Mexico (2021-2030)
  • Table 18 Next-Generation Sequencing Market Analysis in Europe (2021-2030)
  • Table 19 Next-Generation Sequencing Market Analysis in Europe by Product Type (2021-2030)
  • Table 20 Next-Generation Sequencing Market Analysis in Europe by Sequencing Type (2021-2030)
  • Table 21 Next-Generation Sequencing Market Analysis in Europe by Application (2021-2030)
  • Table 22 Next-Generation Sequencing Market Analysis in Europe by End User (2021-2030)
  • Table 23 Next-Generation Sequencing Market Analysis in Europe by Country (2021-2030)
  • Table 24 Next-Generation Sequencing Market Analysis in France (2021-2030)
  • Table 25 Next-Generation Sequencing Market Analysis in Germany (2021-2030)
  • Table 26 Next-Generation Sequencing Market Analysis in the UK (2021-2030)
  • Table 27 Next-Generation Sequencing Market Analysis in Italy (2021-2030)
  • Table 28 Next-Generation Sequencing Market Analysis in Spain (2021-2030)
  • Table 29 Next-Generation Sequencing Market Analysis in Russia (2021-2030)
  • Table 30 Next-Generation Sequencing Market Analysis in Rest of Europe (2021-2030)
  • Table 31 Next-Generation Sequencing Market Analysis in Asia-Pacific (2021-2030)
  • Table 32 Next-Generation Sequencing Market Analysis in Asia-Pacific by Product Type (2021-2030)
  • Table 33 Next-Generation Sequencing Market Analysis in Asia-Pacific by Sequencing Type (2021-2030)
  • Table 34 Next-Generation Sequencing Market Analysis in Asia-Pacific by Application (2021-2030)
  • Table 35 Next-Generation Sequencing Market Analysis in Asia-Pacific by End User (2021-2030)
  • Table 36 Next-Generation Sequencing Market Analysis in Asia-Pacific by Country (2021-2030)
  • Table 37 Next-Generation Sequencing Market Analysis in China (2021-2030)
  • Table 38 Next-Generation Sequencing Market Analysis in Japan (2021-2030)
  • Table 39 Next-Generation Sequencing Market Analysis in India (2021-2030)
  • Table 40 Next-Generation Sequencing Market Analysis in Australia (2021-2030)
  • Table 41 Next-Generation Sequencing Market Analysis in South Korea (2021-2030)
  • Table 42 Next-Generation Sequencing Market Analysis in Rest of Asia-Pacific (2021-2030)
  • Table 43 Next-Generation Sequencing Market Analysis in Rest of World (2021-2030)
  • Table 44 Next-Generation Sequencing Market Analysis in Rest of World by Product Type (2021-2030)
  • Table 45 Next-Generation Sequencing Market Analysis in Rest of World by Sequencing Type (2021-2030)
  • Table 46 Next-Generation Sequencing Market Analysis in Rest of World by Application (2021-2030)
  • Table 47 Next-Generation Sequencing Market Analysis in Rest of World by End User (2021-2030)
  • Table 48 Next-Generation Sequencing Market Analysis in Rest of World by Country (2021-2030)
  • Table 49 Next-Generation Sequencing Market Analysis in the Middle East (2021-2030)
  • Table 50 Next-Generation Sequencing Market Analysis in Africa (2021-2030)
  • Table 51 Next-Generation Sequencing Market Analysis in South America (2021-2030)

List of Figures

  • Figure 1 Competitive Analysis
  • Figure 2 COVID-19 Impact Analysis on Next-Generation Sequencing Market
  • Figure 3 Next-Generation Sequencing Market Analysis in Global (2021-2030)
  • Figure 4 Next-Generation Sequencing Market Analysis in Global by Product Type (2021-2030)
  • Figure 5 Next-Generation Sequencing Market Analysis in Global by Sequencing Type (2021-2030)
  • Figure 6 Next-Generation Sequencing Market Analysis in Global by Application (2021-2030)
  • Figure 7 Next-Generation Sequencing Market Analysis in Global by End User (2021-2030)
  • Figure 8 Next-Generation Sequencing Market Analysis in Global by Geography (2021-2030)
  • Figure 9 Next-Generation Sequencing Market Analysis in North America (2021-2030)
  • Figure 10 Next-Generation Sequencing Market Analysis in North America by Product Type (2021-2030)
  • Figure 11 Next-Generation Sequencing Market Analysis in North America by Sequencing Type (2021-2030)
  • Figure 12 Next-Generation Sequencing Market Analysis in North America by Application (2021-2030)
  • Figure 13 Next-Generation Sequencing Market Analysis in North America by End User (2021-2030)
  • Figure 14 Next-Generation Sequencing Market Analysis in North America by Country (2021-2030)
  • Figure 15 Next-Generation Sequencing Market Analysis in the US (2021-2030)
  • Figure 16 Next-Generation Sequencing Market Analysis in Canada (2021-2030)
  • Figure 17 Next-Generation Sequencing Market Analysis in Mexico (2021-2030)
  • Figure 18 Next-Generation Sequencing Market Analysis in Europe (2021-2030)
  • Figure 19 Next-Generation Sequencing Market Analysis in Europe by Product Type (2021-2030)
  • Figure 20 Next-Generation Sequencing Market Analysis in Europe by Sequencing Type (2021-2030)
  • Figure 21 Next-Generation Sequencing Market Analysis in Europe by Application (2021-2030)
  • Figure 22 Next-Generation Sequencing Market Analysis in Europe by End User (2021-2030)
  • Figure 23 Next-Generation Sequencing Market Analysis in Europe by Country (2021-2030)
  • Figure 24 Next-Generation Sequencing Market Analysis in France (2021-2030)
  • Figure 25 Next-Generation Sequencing Market Analysis in Germany (2021-2030)
  • Figure 26 Next-Generation Sequencing Market Analysis in the UK (2021-2030)
  • Figure 27 Next-Generation Sequencing Market Analysis in Italy (2021-2030)
  • Figure 28 Next-Generation Sequencing Market Analysis in Spain (2021-2030)
  • Figure 29 Next-Generation Sequencing Market Analysis in Russia (2021-2030)
  • Figure 30 Next-Generation Sequencing Market Analysis in Rest of Europe (2021-2030)
  • Figure 31 Next-Generation Sequencing Market Analysis in Asia-Pacific (2021-2030)
  • Figure 32 Next-Generation Sequencing Market Analysis in Asia-Pacific by Product Type (2021-2030)
  • Figure 33 Next-Generation Sequencing Market Analysis in Asia-Pacific by Sequencing Type (2021-2030)
  • Figure 34 Next-Generation Sequencing Market Analysis in Asia-Pacific by Application (2021-2030)
  • Figure 35 Next-Generation Sequencing Market Analysis in Asia-Pacific by End User (2021-2030)
  • Figure 36 Next-Generation Sequencing Market Analysis in Asia-Pacific by Country (2021-2030)
  • Figure 37 Next-Generation Sequencing Market Analysis in China (2021-2030)
  • Figure 38 Next-Generation Sequencing Market Analysis in Japan (2021-2030)
  • Figure 39 Next-Generation Sequencing Market Analysis in India (2021-2030)
  • Figure 40 Next-Generation Sequencing Market Analysis in Australia (2021-2030)
  • Figure 41 Next-Generation Sequencing Market Analysis in South Korea (2021-2030)
  • Figure 42 Next-Generation Sequencing Market Analysis in Rest of Asia-Pacific (2021-2030)
  • Figure 43 Next-Generation Sequencing Market Analysis in Rest of World (2021-2030)
  • Figure 44 Next-Generation Sequencing Market Analysis in Rest of World by Product Type (2021-2030)
  • Figure 45 Next-Generation Sequencing Market Analysis in Rest of World by Sequencing Type (2021-2030)
  • Figure 46 Next-Generation Sequencing Market Analysis in Rest of World by Application (2021-2030)
  • Figure 47 Next-Generation Sequencing Market Analysis in Rest of World by End User (2021-2030)
  • Figure 48 Next-Generation Sequencing Market Analysis in Rest of World by Country (2021-2030)
  • Figure 49 Next-Generation Sequencing Market Analysis in the Middle East (2021-2030)
  • Figure 50 Next-Generation Sequencing Market Analysis in Africa (2021-2030)
  • Figure 51 Next-Generation Sequencing Market Analysis in South America (2021-2030)
  • Figure 52 Market Drivers
  • Figure 53 Market Barriers
  • Figure 54 Market Opportunities
  • Figure 55 PORTER's Five Force Analysis